Table 4 Univariate analysis of factors for 28-day mortality in patients with infections caused by CRKP-BSI
Variable | Death (N = 90) | Survivors (N = 122) | P value |
|---|---|---|---|
Male, n, (%) | 56 (62.2) | 82 (67.2) | 0.451 |
Age(y), mean ± SD | 61.1 ± 17.7 | 60.7 ± 14.8 | 0.900 |
Comorbidities- No., % | |||
 Congestive heart failure | 14 (15.6) | 8 (6.6) | 0.034 |
 Cerebrovascular disease | 18 (20.0) | 22 (18.0) | 0.717 |
 Chronic lung diseases | 22 (24.4) | 30 (24.6) | 0.981 |
 Hepatobiliary and pancreatic diseases | 17 (18.9) | 13 (10.7) | 0.089 |
 Kidney diseases | 24 (26.7) | 32 (26.2) | 0.943 |
 Hematologic malignancy | 26 (28.9) | 28 (23.0) | 0.327 |
 Solid tumor | 14 (15.6) | 26 (21.3) | 0.290 |
 Solid organ transplantation | 9 (10.0) | 10 (8.2) | 0.650 |
 Diabetes mellitus | 12 (13.3) | 24 (19.7) | 0.224 |
 Immune diseases | 10 (11.1) | 8 (6.6) | 0.240 |
 Charlson comorbidity index ≥ 3 | 46 (51.1) | 66 (54.1) | 0.667 |
Pre-infection healthcare interventions-No., % | |||
 Enemac | 9 (10.0) | 9 (7.4) | 0.498 |
 Nasogastric catheterb | 14 (15.6) | 32 (26.2) | 0.062 |
 Urinary catheterb | 34 (37.8) | 48 (39.3) | 0.817 |
 Surgical drainb | 16 (17.8) | 22 (18.0) | 0.962 |
 Central venous catheterb | 30 (33.3) | 34 (27.9) | 0.392 |
 Peripheral arterial catheterb | 15 (16.7) | 11 (9.0) | 0.093 |
 Blood purificationb | 19 (21.1) | 9 (7.4) | 0.004 |
 Tracheal cannulab | 47 (48.9) | 44 (38.5) | 0.132 |
 Tracheostomyb | 11 (12.2) | 9 (7.4) | 0.233 |
 Mechanical ventilationc | 36 (40.0) | 28 (23.0) | 0.008 |
 Gastroscopyc | 3 (3.3) | 3 (2.5) | 0.704 |
 Colonoscopyc | 2 (2.2) | 1 (0.8) | 0.393 |
 Bronchoscopyc | 14 (15.6) | 10 (8.2) | 0.095 |
 Sputum suctionb | 52 (57.8) | 63 (51.6) | 0.375 |
 Thoracentesisb | 11 (12.2) | 10 (8.2) | 0.332 |
 Abdominocentesisb | 6 (6.7) | 6 (5.7) | 0.586 |
 Bone marrow punctureb | 14 (15.6) | 19 (15.6) | 0.997 |
 Lumbar punctureb | 11 (12.2) | 14 (11.5) | 0.868 |
 Previous surgeryb | 26 (28.9) | 32 (26.2) | 0.668 |
 Parenteral nutritionb | 37 (41.1) | 40 (32.8) | 0.213 |
 Previous hospitalizationa | 60 (66.7) | 74 (60.7) | 0.370 |
Previous treatments administeredb-No., % | |||
 Corticosteroids | 38 (42.2) | 14 (11.5) | < 0.001 |
 Chemotherapy or radiotherapy | 12 (13.3) | 28 (23.0) | 0.077 |
 Inadequate empirical antibiotic therapy | 78 (86.7) | 18 (14.8) | < 0.001 |
 Previous use of antibiotics | |||
  Carbapenems | 30 (33.3) | 38 (31.1) | 0.736 |
  Glycopeptides | 22 (24.4) | 26 (21.3) | 0.590 |
  Quinolones | 34 (37.8) | 40 (32.8) | 0.451 |
  3rd/4th generation cephalosporins | 14 (15.6) | 24 (19.7) | 0.440 |
  1st/2nd generation cephalosporins | 10 (11.1) | 15 (12.3) | 0.792 |
  Penicillin | 4 (4.4) | 4 (3.3) | 0.660 |
  β-lactamase inhibitor | 49 (54.4) | 52 (42.6) | 0.088 |
  Aminoglycosides | 5 (5.6) | 7 (5.7) | 0.995 |
  Linezolid | 4 (4.4) | 10 (8.2) | 0.277 |
  Tigecycline | 13 (14.4) | 15 (12.3) | 0.648 |
  Daptomycin | 1 (1.1) | 1 (0.8) | 0.828 |
  Nitroimidazoles | 6 (6.7) | 7 (5.7) | 0.781 |
Source of BSI- No., % | |||
 Primary | 44 (48.9) | 68 (55.7) | 0.323 |
 KP detection in samples from other sites | 55 (61.1) | 61 (50.0) | 0.108 |
  Pulmonary | 20 (22.2) | 36 (29.5) | 0.234 |
  Pleural effusion | 2 (2.2) | 4 (3.3) | 0.647 |
  Pancreaticobiliary tract infection | 8 (8.9) | 6 (4.9) | 0.250 |
  Live abscess | 5 (5.6) | 7 (5.7) | 0.995 |
  Urinary tract infection | 7 (7.8) | 4 (3.3) | 0.144 |
  Intestinal infection | 4 (4.4) | 2 (1.6) | 0.223 |
  Intra-abdominal infection | 3 (3.3) | 2 (1.6) | 0.422 |
  Skin infection | 3 (3.3) | 1 (0.8) | 0.184 |
  Cerebrospinal fluid | 2 (2.2) | 0 (3.3) | 0.098 |
Ward at the onset of BSI- No., % | |||
 Intensive care units | 62 (68.9) | 58 (47.5) | 0.002 |
 Medical wards | 18 (20.0) | 36 (29.5) | 0.116 |
 Surgical wards | 10 (11.1) | 28 (23.0) | 0.026 |
Severity at BSI onset- No., % | |||
 APACHE II score > 15 | 45 (50.0) | 41 (33.6) | 0.016 |
 Severe sepsis/septic shock | 60 (66.7) | 28 (23.0) | < 0.001 |
Therapeutic management-No., % | |||
 Monotherapy | 7 (7.8) | 20 (16.4) | 0.063 |
 Combination therapy | 83 (93.3) | 102 (83.6) | 0.063 |
  Combination with high doses of carbapenem | 30 (33.3) | 96 (78.7) | < 0.001 |
  Tigecycline containing regimen | 38 (42.2) | 46 (37.7) | 0.506 |
  Aminoglycoside containing regimen | 30 (33.3) | 28 (23.0) | 0.094 |
  Polymyxin B containing regimen | 12 (13.3) | 16 (13.1) | 0.963 |
  Ceftazidime and avibactam containing regimen | 10 (11.1) | 8 (6.6) | 0.240 |